Essential Premium

Hedge Funds Hope to Cash In on Perceptive Advisors’ SPAC

Biopharma hedge funds have lined up for stakes in a recent merger involving a blank-check company.

Biopharma Funds Deliver Market-Beating Returns as Valuations Snap Back

With blockbuster gains in 2025 and Wall Street asserting that investors overreacted to government cuts at the FDA, hedge funds focused on life sciences are emerging as some of the industry’s biggest winners.

Sponsored

What’s Behind the Latest Surge in Grain and Oilseed Prices?

Tulip Trend and Quantedge Lead November Gains for CTAs

A handful of managed futures funds posted standout returns last month, with Tulip surging 8 percent and Quantedge cementing double-digit gains for the year.

Related Content

RA Capital Doubles Down on Private Deals as Year-End Frenzy Builds

Stephen Taub

Why Wall Street Veteran Scott Bok Sees Trouble Ahead for Endowments and Private Equity

Michelle Celarier

From the Archive: Institutional Investor’s 2025 Hedge Fund Rising Stars

Michelle Celarier

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram